1.0 **PURPOSE/BACKGROUND**
The purpose of this Standard Operating Procedure (SOP) is to establish a standard for study monitoring visits in the CCCTO and to ensure that the guidelines for the preparation of the monitoring visits and the procedures during monitoring visits are followed.

2.0 **SCOPE**
This SOP applies to all studies that involve a study monitor visit from an outside agency to perform study monitoring.

3.0 **RESPONSIBILITY**
- Study Staff
- Investigational Drug Pharmacy
- Study Sponsors and their designees
- CCCTO Budget staff
- Others as required

4.0 **DEFINITIONS**
Refer to Glossary of Common Terms and Definitions.

**Monitoring**: the act of overseeing the progress of a clinical trial, and of ensuring that it is conducted, recorded and reported in accordance with the protocol, Standard Operating Procedures, Good Clinical Practice (GCP) and the applicable regulatory requirements.

5.0 **ROLES AND PROCEDURES**
5.1 **Scheduling & Notification**
5.1.1 Monitoring visits must be arranged in advance. Study coordinator must notify the required participants of the monitoring visit and confirm availability. Availability of monitoring space must also be confirmed. After the date is agreed upon, the site must receive notice in writing of the visit at least two weeks prior to arrival, unless an exception is granted by the research manager. The notice of the monitoring visit must also include the focus of the visit and a list of required participants during the visit (study coordinator, PI, sub-I, Pharmacy, Regulatory, clinical research assistant, etc.)

5.1.2 Monitor visits will be conducted at a frequency specified in the clinical trial agreement. If the agreed upon frequency is not adhered to, the CCCTO may
seek additional financial compensation and the CCCTO Budget Office will invoice the sponsor accordingly.

5.1.3 If a monitor requests individual access to EPIC, an appointment must be requested with Heath Information Management (HIM) at least two weeks prior to each visit. Otherwise shadow charts will be provided (preferred). Study monitors may request to “look over study coordinator’s shoulder” in EPIC to verify the shadow chart is indeed complete.

5.2 Preparation
5.2.1 Study staff must make arrangements to reserve an appropriate monitoring area. The area should be equipped with (or in close proximity to) a copier, data portal, and fax machine.

5.2.2 Study staff must prepare for visits by ensuring that all the relevant documents in the regulatory binders and the subject binders are gathered and appropriately updated and any outstanding action items have been addressed.

5.3 During the Monitoring visit
5.3.1 Monitors must wear a name badge during their visit identifying them and the organization that they represent or an MCW CCCTO Visitor Badge, which will be provided.

5.3.2 The study monitor must comply with the MCW/FH dress code while on site.

5.3.3 Monitors will be asked to follow the Froedtert Health “Observer Policy” and sign the Observer Form, as appropriate. Refusal of this policy will be documented. The Observer paperwork will be scanned to the study’s regulatory file and the originals will be discarded.

5.3.4 No food/meals will be provided to monitors; however they will be directed to an area where food may be purchased.

5.3.5 A time for the monitor and the study staff to meet for debriefing should be identified and applicable study staff should be notified if their presence is requested (i.e. study coordinator, regulatory staff, research manager, clinical research assistant, etc.).

5.3.6 Study coordinators will meet with study monitors during agreed upon intervals throughout the day and action items should be addressed at those times and/or at the debriefing.

5.3.7 Monitors must present the study coordinator with a written or typed list of findings during the debriefing (Any sticky notes or flags in the patient charts should be referenced on the list).

5.3.8 The study staff will work to resolve all outstanding issues prior to the next scheduled visit.

5.3.9 Every effort will be made to schedule time with the Principal Investigator. If a meeting cannot be arranged, an alternative form of contact may be arranged upon request (i.e. phone call, repeat visit).
5.3.10 Monitors must meet with the staff in an area where confidentiality can be maintained appropriately. Confidential study information should not be discussed in the presence of other study monitors. If necessary, a space can be arranged for private discussions.

5.3.11 If the monitor previously requested an appointment in HIM to access EPIC, the study coordinator will arrange this with HIM in advance. The monitor may not take any shadow charts or study documents out of the CCCTO (laptops, tablets, & notepads are allowed inside HIM.) The study coordinator may escort the monitor to HIM, if necessary, however, will not be present during the HIM appointment. Any questions that arise during the HIM appointment should be addressed at the scheduled debriefing (see 5.3.5).

5.3.12 Study monitoring visits may only be conducted during the CCCTO study coordinator’s normal working hours. Any exception must be approved by the research manager.

5.3.13 Study monitors are required to send a follow-up letter within two weeks following the visit. Study staff may request corrections to the letter if applicable.

6.0 REFERENCES
Froedtert Hospital Policy #RI-016 “Case Management Inspector Release”

Froedtert Health Policy #CPM.0116 “Observer Policy”

Froedtert Health Policy #FCH-HR.002 “Dress Code – Personal Appearance”

Medical College of Wisconsin Policy #HR.EE.150 “Personal Appearance for Employees and Volunteers”

7.0 APPENDICES
N/A

Authorized by:  
James Thomas, Medical Director  
Betty Oleson, CTO Administrative Director
Revision dates:
3/25/13, v 1.0
3/7/14, v 2.0

Review dates:
3/7/14